• Profile
Close

Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study

Vaccine Jan 24, 2018

Zaman K, et al. - A 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed to support vaccination programs in developing countries. This study, conducted in Bangladesh, represented an attempt to evaluate immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose vs licensed 1-dose vial presentation in infants. Findings demonstrated the immunologic non-inferiority of PHiD-CV 4-dose vial (with preservative), compared with PHiD-CV 1-dose vial (preservative-free). In addition, researchers noted that for both presentations, immune responses and reactogenicity following primary/booster vaccination were within similar ranges. Notably, PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay